Key clinical findings include: Gallbladder events were observed throughout the treatment period The FDA recommends informing patients of characteristic symptoms of cholelithiasis and cholecystitis If cholelithiasis is suspected, appropriate clinical evaluation and treatment are indicated Patients generally responded to standard medical or surgical management Clinicians should interpret these data within the broader context of tirzepatide's substantial metabolic benefits, including significant improvements in glycemic control, cardiovascular risk factors, and weight-related comorbidities, while maintaining appropriate vigilance for gallbladder complications
2014;Aug;71(2):350-358
Novo Nordisk, the maker of Wegovy, sent this statement: "The FDA is currently conducting a comprehensive epidemiological study to evaluate the potential safety signal and has not revised the currently approved labels for GLP-1 therapies to include NAION as a potential side effect
Thats a recipe for failure
For monocular patients, the risk is higher, and the risk-benefit analysis is different because even though the odds ratio is probably the same, the risk for harm and the severity of that harm has to be individualized
The SM1 voxel was centered on the right central sulcus, posterior to the hand-knob(Yousry et al., 1997) in the axial plane and rotated to align with the cortical surface(Puts et al., 2011)
